Literature DB >> 9140116

Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

K Midoro1, K Gotoh, T Houkan, K Yukishige, K Fujiwara, K Ootsu.   

Abstract

The antitumor activity of recombinant human interleukin 2 (rIL-2) in combination with 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR) against marine colon carcinoma 26 (Colon 26) was studied. BALB/c mice were treated daily for 15 days with 5'-DFUR, rIL-2 or both, beginning on day 7 after subcutaneous transplantation of Colon 26. While mice treated with 5'-DFUR or rIL-2 alone died of tumor growth with pulmonary metastases within 9 weeks posttransplantation, the survival time was significantly prolonged in mice treated with both 5'-DFUR and rIL-2. Most of the combination-treated animals showed the regression of local tumors and the inhibition of pulmonary metastasis. Histopathologically, many tumor cells were degenerated and necrotized, with marked infiltration of mononuclear cells including large granular lymphocytes (LGLs) with periodic acid-Schiff-positive cytoplasmic granules. The cells were positive for CD3 epsilon, asialo GM1 and NK1.1. Spleen cells from the combination-treated mice showed high activities of natural killer (NK) cytotoxicity as well as growth inhibition of Colon 26 and Meth A fibrosarcoma in mice. The results suggest that the combination therapy of 5'-DFUR plus rIL-2 enhanced non-specific cytotoxicity of LGL/NK cells for Colon 26 in tumor-bearing mice and was effective in the inhibition of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140116      PMCID: PMC5921383          DOI: 10.1111/j.1349-7006.1997.tb00382.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  37 in total

1.  Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

Authors:  R O Dillman; C Church; R K Oldham; W H West; L Schwartzberg; R Birch
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

Review 2.  Recombinant interleukin-2 in cancer: basic and clinical aspects.

Authors:  L T Vlasveld; E M Rankin
Journal:  Cancer Treat Rev       Date:  1994-07       Impact factor: 12.111

3.  Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.

Authors:  H T Tevaearai; P L Laurent; L Suardet; J F Eliason; J C Givel; N Odartchenko
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

4.  5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle.

Authors:  Y Tomita; T Imai; A Katagiri; M Kimura; K Saitoh; S Sato
Journal:  Cancer Lett       Date:  1993-11-30       Impact factor: 8.679

5.  Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.

Authors:  P Ragnhammar; H Blomgren; D Edler; G Lundell; I Magnusson; T Sonnenfeld
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

6.  Experimental and clinical studies on the anticancer agent, doxifluridine (5'-DFUR), Satellite symposium to the 25th annual meeting of the Japan Society for Cancer Therapy. Sapporo, Japan, 7 October 1987. Abstracts.

Authors: 
Journal:  J Int Med Res       Date:  1988       Impact factor: 1.671

7.  Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.

Authors:  Y Ohta; K Sueki; K Kitta; K Takemoto; H Ishitsuka; Y Yagi
Journal:  Gan       Date:  1980-04

8.  A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.

Authors:  T J Hamblin; S Sadullah; P Williamson; J Stevenson; R Oskam; P Palmer; C R Franks
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

9.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; T Ishikawa; T Ohiwa; K Tatsuno; Y Tanaka; H Ishitsuka
Journal:  Jpn J Cancer Res       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.